Merus, a Netherlands-based biopharmaceutical company for human antibody therapeutics, has met the second milestone in its option agreement with Switzerland-based drugs maker Novartis’s corporate venturing unit. Novartis Option Fund, part of the $850m Novartis Venture Funds team, will pay an undisclosed amount for the milestone. In January 2010, Merus entered into a $200m option agreement…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
